ISPOR - EE375 Cost Savings and the Opportunity for Expanded Treatment Access with Increased Use of Biosimilar Adalimumab in the United States

Full Text

EE375 Cost Savings and the Opportunity for Expanded Treatment Access with Increased Use of Biosimilar Adalimumab in the United States

Abstract

Authors

K Shastri K Clarke M. Ainslie-Garcia N Ferko

Back to Volume 27, Supplemental Issue 6S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now